Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response
- 26 September 2009
- journal article
- research article
- Published by Springer Nature in Annals of Hematology
- Vol. 89 (4) , 385-389
Abstract
Angiogenesis plays a significant role in the pathogenesis of multiple myeloma (MM). We have measured concentrations of angiogenesis activators, including vascular endothelial growth factor (VEGF), basic fibroblast growth factor, and hepatocyte growth factor (HGF), and inhibitors, including endostatin, thrombospondin-1 (TSP-1), and angiostatin in the peripheral and bone marrow blood of MM patients at diagnosis and after high-dose chemotherapy. We have analyzed 96 patients with secretory MM. Serial measurements of angiogenesis factors/inhibitors were analyzed in the plasma by subgroups based on the best treatment response. Concentrations of angiogenic factors were determined in the peripheral blood and bone marrow plasma. There were significant decreases of VEGF and HGF levels and a significant increase in TSP-1 concentrations in the bone marrow plasma of patients who achieved complete or very good partial response in contrast to those who had partial or no response. VEGF and HGF levels decrease but those of TSP-1 increase after successful treatment for MM, indicating a reduction in the rate of angiogenesis.Keywords
This publication has 19 references indexed in Scilit:
- NK4, an antagonist of hepatocyte growth factor (HGF), inhibits growth of multiple myeloma cells: molecular targeting of angiogenic growth factorBlood, 2006
- HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myelomaBlood, 2006
- Bone marrow angiogenesis in multiple myelomaLeukemia, 2005
- Increased expression of vascular endothelial growth factor in bone marrow of multiple myeloma patientsEuropean Journal of Internal Medicine, 2003
- High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatmentMediators of Inflammation, 2003
- Elevated Level of Plasma Basic Fibroblast Growth Factor in Multiple Myeloma Correlates with Increased Disease ActivityJapanese Journal of Cancer Research, 2002
- Angiogenic and Lymphangiogenic Molecules in Hematological MalignanciesLeukemia & Lymphoma, 2002
- Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myelomaEuropean Journal of Haematology, 2001
- A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple MyelomaNew England Journal of Medicine, 1996
- Bone marrow angiogenesis and progression in multiple myelomaBritish Journal of Haematology, 1994